Galectin Therapeutics Inc. (GALT)
| Market Cap | 346.92M +49.3% |
| Revenue (ttm) | n/a |
| Net Income | -28.03M |
| EPS | -0.43 |
| Shares Out | 100.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 388,190 |
| Open | 3.500 |
| Previous Close | 3.530 |
| Day's Range | 3.200 - 3.546 |
| 52-Week Range | 2.025 - 7.130 |
| Beta | 0.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About GALT
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company’s lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin... [Read more]
Financial Performance
Financial StatementsNews
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and p...
Galectin Therapeutics Quarterly report: Q2 2026
Galectin Therapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
Galectin Therapeutics Earnings release: Q2 2026
Galectin Therapeutics released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitaliz...
Galectin Therapeutics reaches alignment with FDA on belapectin pathway
Galectin Therapeutics (GALT) announced feedback from its recent in person Type C meeting with the FDA, supporting the advancement of belapectin for the treatment of patients with metabolic dysfunction...
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today anno...
Galectin Therapeutics presents belapectin data at EASL 2026
Galectin Therapeutics (GALT) announced the oral and poster presentations of new analyses from its global NAVIGATE trial of belapectin at the European Association for the Study of the Liver Congress…
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis
NORCROSS, Ga., May 27, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH c...
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and pr...
Galectin Therapeutics Quarterly report: Q1 2026
Galectin Therapeutics has published its Q1 2026 quarterly earnings report on May 15, 2026.
Galectin Therapeutics Earnings release: Q1 2026
Galectin Therapeutics released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Galectin Therapeutics publishes NAVIGATE Phase 2b trial results
Galectin Therapeutics (GALT) announced the publication of results from its NAVIGATE Phase 2b clinical trial evaluating belapectin in patients with MASH cirrhosis and portal hypertension in AASLD flags...
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
NORCROSS, Ga., May 11, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH ...
Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Galectin Therapeutics, Inc., (“Galectin" or the "Company") (NASDAQ: GALT) investors that the firm has initiated an investig...
Galectin Therapeutics files $200M mixed securities shelf
16:13 EDT Galectin Therapeutics (GALT) files $200M mixed securities shelf
Galectin Therapeutics Registration statement: Registration filing
Galectin Therapeutics filed a registration statement on March 31, 2026, providing details about a securities offering with the SEC.
Galectin Therapeutics Earnings release: Q4 2025
Galectin Therapeutics released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Galectin Therapeutics Annual report: Q4 2025
Galectin Therapeutics has published its Q4 2025 annual report on March 31, 2026.
Galectin Therapeutics appoints Henry Brem to board of directors
Galectin Therapeutics (GALT) has appointed Henry Brem, M.D., as an independent director to its Board of Directors. Dr. Brem is an internationally recognized neurosurgeon-scientist and leader in transl...
Galectin Therapeutics Transcript: KOL event
Belapectin demonstrated significant reduction in new esophageal varices and improvement in key fibrosis biomarkers in advanced MASH cirrhosis patients with portal hypertension. The therapy showed a strong safety profile and is uniquely positioned to address an unmet need, with regulatory discussions ongoing.
Galectin Therapeutics provides regulatory update following FDA written response
Galectin Therapeutics (GALT) announced that the U.S. Food and Drug Administration, FDA, has provided a written response, and subsequent communications, to the Company’s previously submitted Type C mee...
Galectin Therapeutics price target raised to $11 from $6 at H.C. Wainwright
H.C. Wainwright analyst Matthew Keller raised the firm’s price target on Galectin Therapeutics (GALT) to $11 from $6 and keeps a Buy rating on the shares. The firm says recent…
Galectin Therapeutics Slides: Corporate presentation
Galectin Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on December 5, 2025.
Galectin Therapeutics Transcript: AGM 2025
The meeting saw the re-election of all directors, approval of executive compensation, and ratification of the auditor. Key updates included strong Navigate trial results for belapectin, ongoing FDA engagement, and strategic planning for future growth.
Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year
“The new NAVIGATE data presented at AASLD further strengthen the clinical and mechanistic profile of belapectin. We continue to see encouraging consistency across key biomarkers-including FibroScan, E...